BMS-813160
Sponsors
Bristol-Myers Squibb, Washington University School of Medicine, Icahn School of Medicine at Mount Sinai
Conditions
Accelerated Intimal HyperplasiaAdvanced CancerColorectal CancerDiabetic Kidney DiseaseHepatocellular CarcinomaNon-small Cell Lung CancerPancreatic CancerPancreatic Ductal Adenocarcinoma
Phase 1
Single Ascending Dose (BMS-813160) Study
CompletedNCT01049165
Start: 2010-02-28End: 2010-11-30Updated: 2011-02-11
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
CompletedNCT03184870
Start: 2017-08-08End: 2023-06-14Updated: 2025-10-09
BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)
CompletedNCT03496662
Start: 2018-08-31End: 2024-07-25Updated: 2025-07-29
Phase 2
Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease
TerminatedNCT01752985
Start: 2013-03-18End: 2015-06-30Updated: 2019-07-30
A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
CompletedNCT02996110
Start: 2017-02-02End: 2021-11-23Updated: 2022-12-19
Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)
Active, not recruitingNCT04123379
Start: 2020-03-05End: 2025-12-31Updated: 2025-01-17